KEY TAKEAWAYS
- The study aimed to isolate native probiotics and assess the effects of beta-glucan and L. rhamnosus Heriz I in patients with breast cancer.
- The findings indicated the potential for Beta Glucan and L. rhamnosus Heriz I as immunomodulatory supplements in chemotherapy, requiring further research.
Alireza Ostadrahimi and the team aimed to isolate a native probiotic and assess the impact of combining Beta Glucan and Lactobacillus rhamnosus Heriz I on White Blood Cell Counts and serum levels of IL-4 and IL-12 in women with breast cancer undergoing chemotherapy.
In this randomized, double-blind, placebo-controlled clinical trial, 30 women with breast cancer participated. Those in the intervention group were administered 2 10-mg capsules of soluble 1-3,1-6, D-beta glucan and 1 capsule of L. rhamnosus strain Heriz I (2 × 107 CFU) daily for 21 days, between 2 courses of chemotherapy, while the placebo group received a placebo during the same period. White blood cell counts, neutrophil, lymphocyte, and monocyte counts, also serum levels of IL-4 and IL-12, were assessed before and after the study.
They isolated L. rhamnosus strain Heriz I was isolated from conventional yogurt of the Heriz region and registered in NCBI GeneBank. Following administration, both groups experienced a decrease in white blood cell counts. The combination group exhibited a decrease in serum IL-4 levels compared to the placebo group (P = 0.005). Additionally, there was a non-significant increase in serum IL-12 levels in the combination group (P= 0.066).
The results indicated the potential for the combination of Beta Glucan and L. rhamnosus Heriz I as immunomodulatory supplements in chemotherapy patients, though further studies are warranted.
No funding-related information was available.
Source: https://pubmed.ncbi.nlm.nih.gov/38777445/
Ostadrahimi A, Ahmadikhatir S, Amirazad H, et al. (2024). “Effect of combination of Beta Glucan and Lactobacillus rhamnosus HerizI on white blood cell counts and serum levels of IL-4 and IL-12 in women with breast cancer undergoing chemotherapy: A randomized double-blind placebo-controlled clinical trial.” Clin Nutr ESPEN. 2024 Jun;61:281-287. doi: 10.1016/j.clnesp.2024.03.035. Epub 2024 Apr 2. PMID: 38777445.
